FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda.
FDA clearance covers pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant disease after one or two prior systemic regimens, introducing PD-1 inhibition into this treatment ...
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved ...
NPPA asks cos to revise prices of 17 drugs following BCD exemption: Gireesh Babu, New Delhi Thursday, February 12, 2026, ...
Bored Panda on MSN
The nastiest thing I’ve witnessed: 38 doctors share their most horrifying delayed cases
Why are people so hesitant to call an ambulance?
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control ...
Our Culture Mag on MSN
Best Ozempic for Weight Loss Through TrimRx: Quality Care Over Quick Fixes
Medical Supervision Separates Effective Programs From Risky Shortcuts Choosing prescription medication for chronic weight management requires understanding how treatment quality varies dramatically.
In an extraordinary gesture, Mondelez World Travel Retail is donating US$1 for every limited-edition, travel retail-exclusive Toblerone Pink Crush bar sold through Qatar Duty Free at Hamad ...
GoodRx reports that the FDA has approved oral semaglutide (Wegovy) for weight loss, offering an alternative to injections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results